Skip to main content

Table 2 COVID-19 patient characteristics

From: Impact of a clinical pharmacist on ultrasound-guided venous thromboembolism screening in hospitalized COVID-19 patients: a pilot prospective study

  Negative VTE (n = 22) Positive for VTE (n = 9) p-Value
Demographics
 Age (years), mean (SD) 59.0 (17.2) 59.5 (14.5)
 Female, n (%) 7 (31.8%) 3 (33.3%)
 BMI (kg/m2), mean (SD) 31.3 (9.1) 32.7 (9.1)
 Prior anticoagulation therapy 0 (0.0%) 0 (0.0%)
Comorbidities, n (%)
 Hypertension 11 (50.0%) 2 (22.2%) 0.15
 Cardiovascular disease 0 (0.00%) 4 (44.4%) 0.0008
 COPD 2 (9.09%) 3 (33.3%) 0.10
 OSA 1 (4.55%) 1 (11.1%) 0.50
 Hepatitis 0 (0.00%) 1 (11.1%) 0.11
 Peripheral vascular disease 1 (4.55%) 1 (11.1%) 0.50
 Malignancy 1 (4.55%) 1 (11.1%) 0.50
 Diabetes 9 (40.9%) 1 (11.1%) 0.10
 Renal failure 1 (4.55%) 4 (44.4%) 0.006
 Paraplegia 0 (0.00%) 1 (11.1%) 0.11
 Singulitis 0 (0.00%) 1 (11.1%) 0.11
Disposition, n (%)
 ICU 0 (0.00%) 5 (55.5%) 0.0001
 Intubation 0 (0.00%) 5 (55.5%) 0.0001
 Death no. 0 (0.00%) 1 (11.1%) 0.11